Antimicrobial Resistance among Gram-Positive Bacteria Isolated in Latin American Hospitals

REFERENCES

• Rice LB. Antimicrobial resistance in gram-positive bacteria. Am J Infect Control. 2006; 34(5 Suppl 1): 511-59.
   Google Scholar
• Karchmer AW, Bayer AS. Methicillin-resistant Staphylo-coccus aureus: an evolving clinical challenge. Clin Infect Dis. 2008; 46 Suppl 5: S342–S3.
   Google Scholar
• Gould IM. Clinical relevance of increasing glycopeptide MICs against Staphylococcus aureus. Int J Antimicrob Agents. 2008; 31 Suppl 2: 1–9.
   PubMedGoogle Scholar
• Sader HS, Moet GJ, Jones RN. Update of the in vitro activity of daptomycin tested 17,193 gram-positive bacterial Isolated from European medical centers (2005-2007). J Chemother. 2009: 21, 5: 500–506.
   PubMed Web of Science ®Google Scholar
• Leclercq R. Epidemiological and resistance issues in mul-tidrug-resistant staphylococci and enterococci. Clin Microbiol In-fect. 2009; 15 (3): 224–31.
   PubMed Web of Science ®Google Scholar
• Segreti J. Efficacy of current agents used in the treatment of Gram-positive infections and the consequences of resistance. Clin Microbiol Infect. 2005; 11 Suppl 3: 29–35.
   PubMed Web of Science ®Google Scholar
• Tverdek FP, Crank CW, Segreti J. Antibiotic therapy of methicillin-resistant Staphylococcus aureus in critical care. Crit Care Clin. 2008; 24 (2): 249–60.
   PubMed Web of Science ®Google Scholar
• Moellering RC. Linezolid: The first oxazolidinone antimi-crobial. Ann Intern Med. 2003; 138 (2): 135–42.
   PubMed Web of Science ®Google Scholar
• Jones RN, Ross JE, Castanheira M, Mendes RE. United States resistance surveillance results for linezolid (LEADER Program for 2007). Diagn Microbiol Infect Dis. 2008; 62 (4): 416–26.
   PubMed Web of Science ®Google Scholar
• Mendes RE, Deshpande LM, Castanheira M, DiPersio J, Saubolle MA, Jones RN. First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States. Antimicrob Agents Chemother. 2008; 52 (6): 2244–6.
   PubMed Web of Science ®Google Scholar
• Trevino M, Martinez-Lamas L, Romero-Jung PA, Giraldez JM, Alvarez-Escudero J, Regueiro BJ. Endemic linezolid-resis-tant Staphylococcus epidermidis in a critical care unit. Eur J Clin Microbiol Infect Dis. 2009; 28 (5): 527–33.
   PubMed Web of Science ®Google Scholar
• Sader HS, Streit JM, Fritsche TR, Jones RN. Antimicro-bial activity of daptomycin against multidrug-resistant Gram-pos-itive strains collected worldwide. Diagn Microbiol Infect Dis. 2004; 50 (3): 201–4.
   PubMed Web of Science ®Google Scholar
• Cubicin. Lexington, (MA): Cubist Pharmaceuticals, Inc; 2008.
   Google Scholar
• Levine DP. Clinical experience with daptomycin: bacter-aemia and endocarditis. J Antimicrob Chemother. 2008; 62 Suppl 3: iii35-iii9.
   Google Scholar
• Livermore DM. Future directions with daptomycin. J An-timicrob Chemother. 2008; 62 Suppl 3: iii41-iii9.
   Google Scholar
• CLSI. M 07-A8. Methods for dilution antimicrobial sus-ceptibility tests for bacteria that grow aerobically; approved stan-dard - eighth edition Wayne, PA: Clinical and Laboratory Standards Institute; 2009.
   Google Scholar
• CLSI. M 100-519. Performance standards for antimicro-bial susceptibility testing. 19th informational supplement Wayne, PA: Clinical and Laboratory Standards Institute; 2009.
   Google Scholar
• Sader HS, Jones RN, Gales AC, Silva JB, Pignatari AC. SENTRY antimicrobial surveillance program report: Latin Amer-ican and Brazilian results for 1997 through 2001. Braz J Infect Dis. 2004; 8 (1): 25–79.
   PubMedGoogle Scholar
• Muto CA, Jernigan JA, Ostrowsky BE, et al. SHEA guide-line for preventing nosocomial transmission of multidrug-resis-tant strains of Staphylococcus aureus and enterococcus. Infect Control Hosp Epidemiol. 2003; 24 (5): 362–86.
   PubMed Web of Science ®Google Scholar
• Sievert DM, Rudrik JT, Patel JB, McDonald LC, Wilkins MJ, Hageman JC. Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006. Clin Infect Dis. 2008; 46 (5): 668–74.
   PubMed Web of Science ®Google Scholar
• Lodise TP, Graves J, Evans A, et al. Relationship between vancomycin MIC and failure among patients with methicillin-re sistant Staphylococcus aureus bacteremia treated with van-comycin. Antimicrob Agents Chemother. 2008; 52 (9): 3315–20.
   PubMed Web of Science ®Google Scholar
• Soriano A, Marco F, Martinez JA, et al. Influence of van-comycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin In-fect Dis. 2008; 46 (2): 193–200.
   PubMed Web of Science ®Google Scholar
• Maor Y, Hagin M, Belausov N, Keller N, Ben-David D, Rahav G. Clinical features of heteroresistant vancomycin-inter-mediate Staphylococcus aureus bacteremia versus those of me-thicillin-resistant S. aureus bacteremia. J Infect Dis. 2009; 199 (5): 619-24.
   Google Scholar
• Liu C, Chambers HF. Staphylococcus aureus with het-erogeneous resistance to vancomycin: Epidemiology, clinical sig-nificance, and critical assessment of diagnostic methods. Antimicrob Agents Chemother. 2003; 47 (10): 3040–5.
   PubMed Web of Science ®Google Scholar
• Traczewski MM, Katz BD, Steenbergen JN, Brown SD. In-hibitory and bactericidal activities of daptomycin, vancomycin, and teicoplanin against methicillin-resistant Staphylococcus au-reus isolates collected from 1985 to 2007. Antimicrob Agents Chemother. 2009; 53 (5): 1735–8.
   PubMed Web of Science ®Google Scholar
• EUCAST. Clinical MIC breakpoints. 2009.
   Google Scholar
• Pankey GA, Sabath LD. Clinical relevance of bacteriosta-tic versus bactericidal mechanisms of action in the treatment of Gram-positive bacterial infections. Clin Infect Dis. 2004; 38 (6): 864–70.
   PubMed Web of Science ®Google Scholar
• Boucher HW, Sakoulas G. Perspectives on daptomycin resistance, with emphasis on resistance in Staphylococcus au-reus. Clin Infect Dis. 2007; 45 (5): 601–8.
   PubMed Web of Science ®Google Scholar
• Sader HS, Jones RN. The activity of daptomycin against wild-type Staphylococcus aureus and strains with reduced sus-ceptibility to vancomycin. Clin Infect Dis. 2006; 43 (6): 798–9.
   PubMed Web of Science ®Google Scholar
• Bantar C, Curcio D, Fernandez Canigia L, Garcia P, Guz-man Blanco M, Leal AL. Comparative in vitro activity of tigecy-cline against bacteria recovered from clinical specimens in Latin America. J Chemother. 2009; 21 (2): 144–52.
   PubMed Web of Science ®Google Scholar
• Hair PI, Keam SJ. Daptomycin: a review of its use in the management of complicated skin and softtissue infections and Staphylococcus aureus bacteraemia. Drugs. 2007; 67 (10): 1483–512.
   PubMed Web of Science ®Google Scholar